Skip to main content

2015 ASCO Annual Meeting

ecancer.org

Interviews and highlights from the 2015 ASCO annual meeting.



rss RSS

SHOW DETAILS
up-solid down-solid
eye
Title
Date Published
Creator
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany
movies
eye 0
favorite 0
comment 0
Dr Baumert talks to ecancertv at ASCO 2015 about the results of her subgroup analysis of molecular markers of a randomised phase III study in patients with a high risk low-grade glioma. The analysis investigated how primary chemotherapy using temozolomide compares to standard radiotherapy, if it prolongs progression-free and overall survival, and whether prognostic molecular factors could be defined.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Allen Lichter, Chief Executive Officer, ASCO, USA
movies
eye 0
favorite 0
comment 0
Dr Lichter presents, at a press conference at ASCO 2015, a new intelligence network called CancerLinQ. CancerLinQ is assembling vast amounts of usable, searchable, real-world cancer information into a powerful database. This data supports efforts to improve quality of care and hasten development of new medicines.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Richard Schilsky - University of Chicago, Chicago, USA
movies
eye 0
favorite 0
comment 0
Dr Schilsky presents, at a press conference at ASCO 2015, the Targeted Agent and Profiling Utilization Registry (TAPUR). It is the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
movies
eye 0
favorite 0
comment 0
Dr Chanan-Khan talks to ecancertv at ASCO 2015 about his analysis of a large phase III study which suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukaemia (CLL) that has worsened despite prior therapy.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA
movies
eye 0
favorite 0
comment 0
Dr Wolchok talks to ecancertv at ASCO 2015 about results from a randomised phase III trial which indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone. These results represent yet another major step forward in tackling melanoma.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Nicholas Turner - The Institute of Cancer Research, London, UK
movies
eye 1
favorite 0
comment 0
Dr Turner talks to ecancertv at ASCO 2015 about the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada
movies
eye 1
favorite 0
comment 0
Prof Margolese presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
movies
eye 1
favorite 0
comment 0
Dr Usmani talks to ecancertv at ASCO 2015 about a phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada
movies
eye 2
favorite 0
comment 0
Prof Margolese talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Gauthier Bouche - Anticancer Fund, Strombeek-Bever, Belgium
movies
eye 2
favorite 0
comment 0
Dr Bouche talks to ecancertv at ASCO 2015 about the Repurposing Drugs in Oncology (ReDO) project, which promotes clinical research on repurposing generic drugs to treat cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Meletios Dimopoulos - University of Athens, Athens, Greece
movies
eye 1
favorite 0
comment 0
Prof Dimopoulos talks to ecancertv about the results from the phase III 'ENDEAVOR' study which looked at carfilzomib and dexamethasone (Kd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM).
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Robert Comis - ECOG-ACRIN Cancer Research Group, Philadelphia, USA
movies
eye 0
favorite 0
comment 0
Dr Comis talks to ecancertv at ASCO 2015 about a National Cancer Institute (NCI) sponsored cancer clinical trial for under-represented populations that aims to refine the calculation of accrual targets.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos
movies
eye 0
favorite 0
comment 0
Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) and Dr Jacqueline Barrientos (LIJ Medical Center, New York, USA) discuss the latest in the treatment of chronic lymphocytic leukaemia (CLL). They consider novel agents and treatment strategies, with a particular focus on new data arising from ASCO 2015. In particular, they discuss chemo combinations with immunology drugs such as rituximab and the use of single agents such as ibrutinib and idelalisib. They note the possible side effects...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA
movies
eye 0
favorite 0
comment 0
Dr Hudis presents, at a press conference at ASCO 2015, three key initiatives designed to advance precision medicine: The National Cancer Institute-MATCH (NCI-MATCH) trial, co-led by the ECOG-ACRIN Cancer Research Group, which is designed to seek evidence that treating patients based on their tumours' molecular profile, rather than by tumour type, may have clinical benefit The Targeted Agent and Profiling Utilization Registry (TAPUR), the first ASCO-led clinical trial, which will offer patients...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
movies
eye 0
favorite 0
comment 0
Dr Usmani presents at a press conference at ASCO 2015 a phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Kevin Harrington - Institute of Cancer Research, London, UK
movies
eye 0
favorite 0
comment 0
Dr Harrington talks to ecancertv at ASCO 2015 about a phase III randomised trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy
movies
eye 0
favorite 0
comment 0
Dr Francesco talks to ecancertv at ASCO 2015 about the data from a study of 720 patient metastatic melanoma patients using ipilimumab 3 mg/kg within the Italian expanded access programme. By analysing a large cohort of ipilimumab-treated advanced melanoma patients, he identified a subpopulation of patients that is very unlikely to benefit from this treatment. Based on these data, responders could be easily selected from general population, allowing for upfront screening that could spare...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Nicholas Turner - The Institute of Cancer Research, London, UK
movies
eye 1
favorite 0
comment 0
Dr Turner presents, at a press conference at ASCO 2015, the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Gary Schwartz - Columbia University, New York, USA
movies
eye 0
favorite 0
comment 0
Dr Schwartz gives an expert commentary on data presented at ASCO 2015. 452 patients with advanced leiomyosarcoma or adipocytic sarcoma, which is also called liposarcoma, were randomly assigned to treatment with eribulin or dacarbazine until disease progression. The median overall survival was 13.5 months in the eribulin group and 11.5 months in the dacarbazine group. Dr Schwartz looks at the implications of this and gives some background on the difficulty of treating sarcomas.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA
movies
eye 0
favorite 0
comment 0
Dr Armstrong presents, at a press conference at ASCO 2015, an analysis of over 34,000 participants in the federally funded Childhood Cancer Survivor Study showing improvement in late mortality achieved over three decades.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
movies
eye 0
favorite 0
comment 0
Dr Mesa presents, at a press conference at ASCO 2015, findings from the PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
movies
eye 0
favorite 0
comment 0
Dr Sehn talks to ecancertv at ASCO 2015 about a phase III study that finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.
movies
eye 0
favorite 0
comment 0
Prof Sandler presents, at a press conference at ASCO 2015, the results of a federally funded phase III study that found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Emiliano Calvo - START Madrid, Madrid, Spain
movies
eye 0
favorite 0
comment 0
Dr Calvo talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC) The treatment induced objective responses in 67% of the patients, including 10% of them where all signs of cancer disappeared. Every patient with SCLC denominated primary chemotherapy-sensitive (their chemotherapy-free interval is more than 90 days) responded to treatment, including...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA
movies
eye 0
favorite 0
comment 0
Dr Wickerham talks to ecancertv at ASCO 2015 about final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) looking at preventing breast cancer. Raloxifene has retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer and continued to grow closer to tamoxifen in preventing noninvasive breast cancer. Raloxifene has also maintained a better profile with respect to uterine disease, thromboembolic events, and...
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
movies
eye 0
favorite 0
comment 0
Prof Chanan-Khan presents, at a press conference at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Ross Camidge - University of Colorado, Denver, USA
movies
eye 0
favorite 0
comment 0
Dr Camidge talks to ecancertv at ASCO 2015 about new treatments for anaplastic lymphoma kinase (ALK) positive lung cancer, including alectinib and brigatinib.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India
movies
eye 3
favorite 0
comment 0
Dr D’Cruz presents, at a press conference at ASCO 2015, a randomised phase III study which resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Simon Chowdhury - Guy's Hospital, London, UK
movies
eye 0
favorite 0
comment 0
Dr Chowdhury talks to ecancertv at ASCO 2015 about the results of the TERRAIN study which looked at the use of 160 mg of enzalutamide taken orally once daily versus bicalutamide at a dose of 50mg taken once daily in combination with an LHRH analogue in patients with metastatic prostate cancer whose disease had progressed despite treatment with luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration. Results showed median progression free survival was 15.7 months in...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
movies
eye 1
favorite 0
comment 0
Dr Schöffski presents, at a press conference at ASCO 2015, findings from a randomised phase III trial point to a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr James Larkin - Royal Marsden Hospital, London, UK
movies
eye 0
favorite 0
comment 0
Dr Larkin talks to ecancertv at ASCO 2015 about the results of a randomised phase II trial of kinase inhibitor lenvatinib used in combination with everolimus in renal cell carcinoma, which saw significant improvements in progression free survival compared with everolimus alone.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
movies
eye 1
favorite 0
comment 0
Dr Mesa talks to ecancertv at ASCO 2015 about findings from the PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
movies
eye 0
favorite 0
comment 0
Dr Sehn presents at a press conference at ASCO 2015 about a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).
2015 ASCO Annual Meeting
Aug 8, 2017 Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley
movies
eye 0
favorite 0
comment 0
Dr Doroshow (National Cancer Institute, Bethesda, USA), Dr Flaherty (Massachusetts General Hospital, Boston, USA) and Dr Conley (Division of Cancer Treatment & Diagnosis, NCI , USA) present, at a press conference at ASCO 2015, about the trial: NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) A clinical trial that will analyse patients’ tumours to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, “actionable mutations”) and assign...
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi
movies
eye 0
favorite 0
comment 0
Prof Sternberg (San Camillo and Forlanini Hospitals, Rome, Italy) chairs a discussion at ASCO 2015 for ecancertv with Prof Clarke (The Christie Hospital, Manchester, UK), Prof Efstathiou (MD Anderson Cancer Center, Houston, USA), and Prof Fizazi (Institut Gustave Roussy, Paris, France) about the latest in novel agents and treatment strategies for prostate cancer. They consider the evolving landscape of castration-resistant prostate cancer (CRPC) treatment and give insight into potential...
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Yilong Wu - President of the Chinese Society of Clinical Oncology
movies
eye 0
favorite 0
comment 0
Prof Wu talks to ecancertv at ASCO 2015 about EGFR inhibition in lung cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr James Spicer - Guy's Hospital, London, UK
movies
eye 0
favorite 0
comment 0
Dr Spicer talks to ecancertv at ASCO 2015, about the progress of recent drug development in lung cancer treatments.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Anil D’Cruz - Tata Memorial Centre, Mumbai, India
movies
eye 2
favorite 0
comment 0
Dr D’Cruz talks to ecancertv at ASCO 2015 about a randomised phase III study which resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
movies
eye 1
favorite 0
comment 0
Prof Gnant talks to ecancertv at ASCO 2015 about the use of adjuvant denosumab to reduce bone problems in postmenopausal women with breast cancer receiving treatment with aromatase inhibitors. Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopaenia, osteoporosis, and fractures - but the addition of adjuvant denosumab to the treatment plan reduces patients' risk of clinical fractures.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
movies
eye 2
favorite 0
comment 0
Dr Schöffski talks to ecancertv at ASCO 2015 about the findings of a randomised phase III trial that point to eribulin as a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA
movies
eye 0
favorite 0
comment 0
Prof Sandler talks to ecancertv at ASCO 2015 about a federally funded phase III study found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localised prostate cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr William Slayton - University of Florida, Gainsville, USA
movies
eye 0
favorite 0
comment 0
Dr Slayton talks to ecancertv at ASCO 2015, about the outcomes of Children's Oncology Group trial AALL0622 in patients 1-30 years old. Treating with dasatinib plus intensive chemotherapy versus stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukaemia. Results showed dasatinib with intensive chemotherapy was well tolerated; subjects with rapid response had excellent outcomes without SCT. Further follow-up and additional trials are necessary to define the...
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Claus Garbe - University of Tübingen, Tübingen, Germany
movies
eye 0
favorite 0
comment 0
Prof Garbe talks to ecancertv at ASCO 2015 about a randomised study which found that surgical removal of the lymph nodes surrounding a melanoma tumour after a positive lymph node biopsy (melanoma found in node) does not improve survival.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Claus Garbe - University of Tübingen, Tübingen, Germany.
movies
eye 0
favorite 0
comment 0
Prof Garbe presents, at a press conference at ASCO 2015, a randomised study finds that surgical removal of the lymph nodes surrounding a melanoma tumour after a positive lymph node biopsy (melanoma found in node) does not improve survival.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Arlene Chan - The Mount Hospital, Perth, Australia
movies
eye 0
favorite 0
comment 0
Prof Chan talks to ecancertv at ASCO 2015, discusses adjuvant targeted therapy for HER2-positive early breast cancer, evaluating the effects of neratinib after adjuvant trastuzumab.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
movies
eye 0
favorite 0
comment 0
Dr Le talks to ecancertv at ASCO 2015 about a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA
movies
eye 0
favorite 0
comment 0
Dr Schuchter gives an expert commentary at ASCO 2015 on immunotherapy data presented on the first day: - A 132-patient study indicating that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC) - Genomic marker predicts anti-PD-1 response in several cancers - Findings from a phase I/II study that suggest that nivolumab is safe and effective in advanced liver cancer - Randomised phase III study indicates PD-1 immunotherapy is an effective...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia
movies
eye 0
favorite 0
comment 0
Dr Zdenkowski talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET. The results show that in postmenopausal women who had completed four or more years of AET for hormone receptor positive breast cancer showed significantly reduced the incidence of late invasive breast cancer...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Merry-Jennifer Markham - University of Florida, Florida, USA
movies
eye 0
favorite 0
comment 0
Dr Markham gives an expert commentary at ASCO 2015 on immunotherapy data presented on the second day: - A phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. - A phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL). - A phase II study that has identified the first...
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
movies
eye 0
favorite 0
comment 0
Dr Anthony El-Khoueiry talks to ecancertv at ASCO 2015 about findings from a phase I/II study that suggest that nivolumab is safe and effective in advanced liver cancer.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Tanguy Seiwert - University of Chicago, Chicago, USA
movies
eye 0
favorite 0
comment 0
Dr Tanguy Seiwert talks to ecancertv at ASCO 2015 about a 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC).
2015 ASCO Annual Meeting
Aug 8, 2017 Dr James Larkin - Royal Marsden Hospital, London, UK
movies
eye 0
favorite 0
comment 0
Dr Larkin talks to ecancertv at ASCO 2015 about an update on a phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma: Progression-free survival and correlative biomarker analysis from the coBRIM trial. Longer follow-up has confirmed the clinical benefit of vemurafenib and cobimetinib in patients with advanced BRAF V600-mutated melanoma. Co-existence of BRAF V600 and baseline activating RAS/RAF/RTK mutations do not seem to affect disease progression or rate of...
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos
movies
eye 0
favorite 0
comment 0
Prof Moreau (Centre Hospitalier Universitaire de Nantes, Nantes, France) chairs a discussion for ecancertv with Prof Lonial (Emory University, Atlanta, USA) and Prof Dimopoulos (University of Athens, Athens, Greece) about the latest in multiple myeloma, including data presented at ASCO 2015. They discuss the latest in protease inhibitors and immunotherapy with particular reference to carfilzomib, bortezomib, and elotuzumab.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
movies
eye 0
favorite 0
comment 0
Dr Steven O'Day talks to ecancertv at ASCO 2015 about the findings from a randomised phase III trial which indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
movies
eye 0
favorite 0
comment 0
Dr Luis Paz-Ares talks to ecancertv at ASCO 2015 about findings from a randomised phase III study that indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Gregory Armstrong - St Jude Children’s Research Hospital, Mempis, USA
movies
eye 0
favorite 0
comment 0
Dr Armstrong talks to ecancertv at ASCO 2015 about an analysis of over 34,000 participants in the federally funded Childhood Cancer Survivor Study showing improvement in late mortality achieved over three decades. Among five-year survivors, all-cause mortality at 15 years of diagnosis dropped from 12.4% to 6%.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Hernán Cortés-Funes - HC Marbella, Marbella, Spain
movies
eye 0
favorite 0
comment 0
Dr Cortés-Funes talks to ecancertv at ASCO 2015 about the exciting new developments in technology at the Marbella​ proton centre, and the advances in proton therapy treatments.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA
movies
eye 0
favorite 0
comment 0
Dr Wolchok presents, at a press conference at ASCO 2015, findings from a randomised phase III trial indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA
movies
eye 0
favorite 0
comment 0
Dr Giaccone talks to ecancertv at ASCO 2015 about his discussion on PDL1 expression in rare thymic tumours, and his recent clinical study with PD1 inhibitors in thymic carcinomas.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy
movies
eye 0
favorite 0
comment 0
Dr Ferrucci talks to ecancertv at ASCO 2015 about the results of a phase III trial comparing nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma. The results showed NIVO alone had superior clinical activity versus IP alone. The results with NIVO plus IPI and NIVO alone further suggest complementary activity of the two agents.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Jan Buckner - Mayo Clinic, Rochester, USA
movies
eye 0
favorite 0
comment 0
Dr Buckner talks to ecancertv at ASCO 2015 about a federally funded phase III trial that is providing additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive function.
2015 ASCO Annual Meeting
Aug 8, 2017 Dr Jan Buckner - Mayo Clinic, Rochester, USA
movies
eye 0
favorite 0
comment 0
Dr Buckner presents, at a press conference at ASCO 2015, a federally funded phase III trial that is providing additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive function.
2015 ASCO Annual Meeting
Aug 8, 2017 Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China
movies
eye 3
favorite 0
comment 0
Dr Han talks to ecancertv at ASCO 2015 about a multicentre retrospective study to evaluate the efficacy of combination therapy over transarterial chemoembolisation (TACE) alone. The study compared the overall survival between patients with ≥ grade 2 sorafenib-related dermatologic adverse events in the combination therapy group and patients treated with TACE alone.
2015 ASCO Annual Meeting
Aug 4, 2017 Dr Tanguy Seiwert - University of Chicago, Chicago, USA
movies
eye 0
favorite 0
comment 0
Dr Tanguy Seiwert presents the results of a 132-patient study that indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC) during a press conference at ASCO 2015.
2015 ASCO Annual Meeting
Aug 4, 2017 Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
movies
eye 0
favorite 0
comment 0
Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).
2015 ASCO Annual Meeting
Aug 4, 2017 Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
movies
eye 0
favorite 0
comment 0
Dr Dung T. Le presents, at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.